Mari Strengell
- Immunology top 5%
- Immune Cell Function and Interaction 5
- Immune Response and Inflammation 3
- T-cell and B-cell Immunology 3
- Immunotherapy and Immune Responses 2
- IL-33, ST2, and ILC Pathways 2
- Epidemiology top 10%
- Influenza Virus Research Studies 5
- Respiratory viral infections research 5
- Modeling and Simulation top 5%
- Virology top 10%
-
- SARS-CoV-2 and COVID-19 Research 2
- Co-authors
- Ilkka JulkunenSampsa MatikainenTimo SarenevaDon FosterAnne LehtonenJukka SirénPamela ÖsterlundNiina Ikonen
- Partner nations
- FinlandUnited StatesSweden
In The Last Decade
Mari Strengell
14 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 78
- Immunology 913
- Epidemiology 456
- Modeling and Simulation 47
- Virology 42
- Oncology 201
Countries citing papers authored by Mari Strengell
This map shows the geographic impact of Mari Strengell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mari Strengell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mari Strengell more than expected).
Fields of papers citing papers by Mari Strengell
This network shows the impact of papers produced by Mari Strengell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mari Strengell. The network helps show where Mari Strengell may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mari Strengell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 7 | |
| 2 | [Influenza viruses--a challenge for vaccinations]. | 2012 | 0 |
| 3 | 2011 | 57 | |
| 4 | Influenssa A(H1N1) 2009 -pandemian toinen epidemia-aalto aiheutti vähemmän kuolemia ja tehohoidon tarvetta | 2011 | 1 |
| 5 | High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland | 2010 | 27 |
| 6 | 2010 | 136 | |
| 7 | 2009 | 130 | |
| 8 | 2009 | 140 | |
| 9 | 2008 | 32 | |
| 10 | 2006 | 72 | |
| 11 | 2004 | 61 | |
| 12 | 2004 | 92 | |
| 13 | 2003 | 332 | |
| 14 | 2002 | 214 | |
| 15 | 2001 | 19 |
About Mari Strengell
Mari Strengell is a scholar working on Immunology, Virology and Infectious Diseases, having authored 15 papers that have together received 1.3k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (5 papers), Respiratory viral infections research (5 papers), Immune Cell Function and Interaction (5 papers), Immune Response and Inflammation (3 papers), T-cell and B-cell Immunology (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Immunotherapy and Immune Responses (2 papers) and IL-33, ST2, and ILC Pathways (2 papers). The work is most often cited by research in Immunology (913 citations), Epidemiology (456 citations) and Modeling and Simulation (47 citations). Mari Strengell has collaborated with scholars based in Finland, United States and Sweden. Frequent co-authors include Ilkka Julkunen, Sampsa Matikainen, Timo Sareneva, Don Foster, Anne Lehtonen, Jukka Sirén, Pamela Österlund, Niina Ikonen, Thedi Ziegler and Jaana Pirhonen. Their work appears in journals such as The Journal of Immunology, PLoS ONE and Journal of Virology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.